Catalog No.
Product Name
Application
Product Information
Citations
-
Drug Impurity
Fluphenazine decanoate impurity 7, a specific impurity of Fluphenazine decanoate, serves as a reference compound in pharmaceutical research. This impurity is significant in assessing the purity and stability of Fluphenazine decanoate formulations. It is utilized in analytical studies to ensure compliance with regulatory standards in drug development processes. -
Drug Impurity
Telmisartan impurity 4 is a structural impurity associated with the antihypertensive agent Telmisartan. This compound is primarily utilized in quality control and analytical studies to assess the purity of pharmaceutical formulations. Its presence is critical for ensuring compliance with regulatory standards in drug development and manufacturing processes. -
Drug Impurity
6-(4-Hydroxyphenoxy)hexyl acetate is a drug impurity characterized by its molecular structure, which can influence the pharmacokinetics of various compounds. This reagent may serve as a critical component for analytical studies aimed at assessing the purity and stability of pharmaceutical formulations. Its role in research is essential for ensuring the safety and efficacy of drug products, facilitating compliance with regulatory standards during the drug development process. -
Drug Impurity
Sildenafil impurity 9 is a chemical impurity associated with the synthesis of Sildenafil, a well-known phosphodiesterase type 5 (PDE5) inhibitor. This impurity serves as a critical reference standard for quality control in pharmaceutical research and development. Its characterization is essential for ensuring the purity and efficacy of Sildenafil formulations in compliance with regulatory standards. -
Drug Impurity
Candesartan impurity 17 is a known impurity associated with the angiotensin II receptor antagonist Candesartan. This compound is pertinent for research focused on the characterization of pharmaceutical formulations, ensuring quality control during the synthesis of Candesartan. It is also useful for studying the potential effects of impurities on pharmacological activity and safety profiles in drug development. -
Drug Impurity
Linagliptin impurity 3 is a known impurity associated with the therapeutic agent Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. It is primarily utilized in pharmaceutical research for the assessment of drug quality and safety, aiding in the development and characterization of pharmaceutical formulations. This compound is essential for regulatory compliance and stability studies in the production of Linagliptin-based medications. -
Drug Impurity
Amlodipine impurity 8 is a drug impurity associated with Amlodipine, a calcium channel blocker. This impurity may arise during the synthesis of Amlodipine and is important for quality control and regulatory compliance in pharmaceutical development. It can also be utilized in analytical studies to assess the purity and stability of Amlodipine formulations. -
Teramycin Impurity
Descladinose 6-N-desmethyl azithromycin is identified as a teramycin impurity. This compound is relevant for studies investigating antibiotic degradation and impurity profiling in the development of macrolide antibiotics. Its presence can provide insights into the stability and purity of teramycin formulations in pharmaceutical research. -
Drug Impurity
(Z)-3-phenyl-2-(propylimino)thiazolidin-4-one acts as a drug impurity and is relevant for pharmaceutical quality control and analytical research. This compound can serve as a reference standard for impurity profiling, aiding in the characterization of thiazolidine derivatives. Its role in ensuring the safety and efficacy of drug formulations makes it an essential reagent for researchers engaged in pharmaceutical development and regulatory compliance. -
Drug Impurity
Ranitidine impurity 15 is a known impurity associated with the pharmaceutical compound ranitidine. This chemical is primarily utilized in the characterization and quality assessment of ranitidine formulations. Its identification is crucial for regulatory compliance and can provide insights into the stability and purity of the drug, supporting research applications in pharmaceutical development and formulation studies. -
Drug Impurity
Atorvastatin impurity 6 is a known impurity associated with the cholesterol-lowering agent Atorvastatin, primarily affecting its pharmacological profile. This compound serves as a critical reference standard in quality control and analytical chemistry, ensuring the purity of Atorvastatin formulations. Its identification and quantification are essential for regulatory compliance and the development of safe and effective pharmaceutical products. -
Drug Impurity
Itraconazole impurity 18 is a known impurity of the antifungal agent Itraconazole. It is used primarily in quality control and analytical research to assess the purity of Itraconazole formulations. The presence of this impurity may impact the pharmacological profile and safety of the drug, making it essential for stability studies and regulatory compliance in pharmaceutical development. -
Drug Impurity
Rivaroxaban impurity 23 is a chemical impurity associated with the anticoagulant Rivaroxaban. Its presence may affect the pharmacological properties and safety profile of the parent compound. This impurity is primarily utilized in research settings for the development, characterization, and quality control of pharmaceutical formulations containing Rivaroxaban. Understanding and analyzing such impurities is crucial for regulatory compliance and enhancing drug safety profiles. -
Drug Impurity
Azilsartan impurity 16, also known as Azilsartan medoxomil O-ethyl ether, is a characterized impurity associated with the antihypertensive agent Azilsartan. Its identification is crucial for ensuring the purity and safety of pharmaceutical formulations. This compound serves as a reference standard in quality control and analytical research applications, facilitating the assessment of Azilsartan's purity in drug development. -
Drug Impurity
Everolimus impurity 12 is a known impurity related to the immunosuppressant Everolimus, which primarily acts by inhibiting the mTOR pathway. This compound is essential for assessing the purity and quality of Everolimus formulations during research and development. It serves as a critical reference standard for analytical methods in pharmaceutical analysis and quality control processes. -
Drug Impurity
Lincomycin impurity 1 is a recognized impurity associated with the antibiotic lincomycin. This compound may serve as a reference standard in analytical chemistry for the assessment of purity and quality control in pharmaceutical formulations. It is particularly relevant in research applications focused on antibiotic efficacy and pharmacokinetics, providing insights into the compound's overall safety and effectiveness. -
Drug Impurity
Terephthalic acid impurity 1 is a known impurity associated with terephthalic acid. This compound is critical in evaluating drug purity and stability, particularly in pharmaceutical formulations involving terephthalic acid. Its presence can influence the overall quality and efficacy of the final product, making it essential for analytical and quality control applications in chemical research. -
Drug Intermediate Control
(Rac)-7-Methoxy propranolol is a key synthetic intermediate that plays a critical role in the production of pharmaceuticals. This compound is utilized in drug formulation and development, particularly in studies related to beta-adrenergic receptor antagonism, which is important for cardiovascular research. Its chemical structure facilitates various synthetic pathways in the creation of effective therapeutics. -
Drug Impurity
Cetirizine impurity 6 is a known impurity associated with the antihistamine Cetirizine. This compound is of interest in pharmaceutical research for its potential effects on drug purity and quality control, particularly in the development and validation of analytical methods. Studies involving Cetirizine impurity 6 contribute to understanding the stability and safety profile of Cetirizine formulations. -
Drug Impurity
Linagliptin impurity 5 is a chemical impurity associated with Linagliptin, a DPP-4 inhibitor used in the management of type 2 diabetes. This impurity serves as an important reference standard for analytical method development and quality control testing in pharmaceutical research. Its analysis is crucial for ensuring the purity and safety of Linagliptin formulations. -
Drug Impurity
Roxithromycin Impurity 3 is an impurity variant of Roxithromycin, a macrolide antibiotic targeting bacterial protein synthesis. This compound is primarily used in the evaluation and characterization of the purity and stability of Roxithromycin formulations. It serves as a valuable tool for researchers investigating antibiotic efficacy and regulatory compliance in pharmaceutical development. -
Drug Impurity
Prasugrel impurity 7 hydrochloride is a known impurity of Prasugrel hydrochloride, a platelet aggregation inhibitor. This compound is utilized in research applications to assess the purity of pharmaceutical formulations and understand the stability and degradation pathways of the active ingredient. It provides essential insights for quality control and regulatory compliance in drug development. -
Drug Impurity
Budesonide impurity 89 is a structural impurity of Budesonide, a glucocorticoid used primarily for its anti-inflammatory properties. This compound is significant for analytical chemistry applications and quality control, particularly in the assessment of pharmaceutical formulations. Its presence can impact the purity profile and safety assessment of Budesonide-containing products. -
Drug Impurity
Ticagrelor impurity 16 is a chemical impurity associated with the antiplatelet agent Ticagrelor. It serves as a vital reference standard for the characterization and quantification of Ticagrelor in pharmaceutical formulations. This compound is essential for ensuring the quality and efficacy of Ticagrelor by assisting in the identification and analysis of impurities during drug development and quality control processes. -
Drug Impurity
Itraconazole impurity 5 is a drug impurity related to the antifungal agent Itraconazole. This compound is used primarily in quality control and analytical studies to evaluate the purity of pharmaceutical formulations. Its presence may affect the efficacy and safety profile of Itraconazole, making it relevant for stability testing and regulatory compliance in pharmaceutical research. -
Drug Impurity
Androstenediol impurity 1 is a drug impurity associated with androgenic compounds. This chemical is utilized in quality control processes to assess the purity of steroid hormone formulations. Its presence is critical for understanding the pharmacological profile and safety of steroid-based therapeutics, making it relevant for researchers in pharmaceutical development and regulatory compliance. -
Drug Impurity
Prasugrel impurity 5, also known as m-Fluoro prasugrel thiolactone, is a known impurity associated with the pharmaceutical compound Prasugrel. It is important for the analysis of drug quality and safety, particularly in the development and validation of analytical methods for pharmaceutical research. This compound is used in studies assessing the impact of drug impurities on pharmacokinetics and pharmacodynamics, contributing to a better understanding of drug metabolism and efficacy. -
Drug Impurity
Ropinirole impurity 10, also known as 3-Hydroxyimino ropinirole, is a chemical impurity associated with the compound Ropinirole. Its presence may be relevant for analytical studies and quality control in pharmaceutical development. This impurity can provide insights into the stability and degradation pathways of Ropinirole, making it an important reagent for researchers focusing on drug formulation and safety assessment. -
Drug Impurity
Rivaroxaban impurity 42, also known as decarbonyl rivaroxaban, is identified as a chemical impurity associated with the anticoagulant Rivaroxaban. This impurity can serve as a critical reference standard for analytical studies, ensuring the quality and purity of Rivaroxaban formulations in pharmaceutical research. It is essential for understanding the metabolic pathways and potential degradation products of Rivaroxaban in drug development and stability testing. -
Drug Impurity
Atenolol impurity 1, also known as Hydroxyatenolol, is a pharmaceutical impurity associated with the beta-blocker Atenolol. This compound is relevant in quality control and analytical chemistry, particularly in the assessment of drug purity and stability. Its characterization is essential for ensuring the safety and efficacy of Atenolol formulations in pharmaceutical research. -
Drug Impurity
Mycophenolate impurity 4 is an impurity associated with Mycophenolate, primarily impacting drug purity assessments. This compound serves as a critical reference standard for analytical methods aimed at quantifying impurities in pharmaceutical preparations. Its identification and characterization are essential in ensuring the quality and safety of Mycophenolate-containing formulations in research and development settings. -
Drug Impurity
Itraconazole impurity 16 is a chemical byproduct associated with the antifungal agent Itraconazole. It is primarily utilized in quality control and analytical research to assess the purity and stability of Itraconazole formulations. This impurity can help in understanding the metabolic pathways of drugs and ensuring compliance with regulatory standards in pharmaceutical development. -
Drug Impurity
Trazodone impurity 6 dihydrochloride is a known impurity derived from trazodone dihydrochloride, primarily studied in relation to drug quality and safety. It serves as a critical reference standard in the analytical evaluation of trazodone formulations and can aid in understanding the stability and degradation profiles of the drug. This compound is essential for researchers focusing on pharmacological studies and quality control in pharmaceutical development. -
Drug Impurity
Ethinylestradiol impurity 4, also known as 6α-Hydroxy Ethynyl Estradiol, is a recognized impurity associated with the synthesis of Ethinylestradiol. This compound serves as an important reference standard for the evaluation of drug purity and quality control in pharmaceutical applications. Its presence and quantitative analysis are crucial in ensuring compliance with regulatory standards in the production of hormonal therapies. -
Drug Impurity
Candesartan impurity 28 is a known impurity associated with Candesartan. It is primarily relevant for quality control and analytical research in the pharmaceutical industry. The characterization of this impurity is essential for assessing the purity and stability of Candesartan formulations. Researchers may utilize this compound to ensure compliance with regulatory standards during the drug development process. -
Drug Impurity
Prednisolone Impurity 5 is a identified impurity of the corticosteroid Prednisolone. Its characterization is essential for quality control in pharmaceutical formulations, ensuring the integrity of the final product. This reagent can be utilized in research focused on drug stability, efficacy, and safety assessments, contributing to the development of reliable corticosteroid therapies. -
Drug Impurity
tert-Butyl 2-(4,5-dibromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylate is a chemical compound identified as a drug impurity. This reagent is primarily utilized for the analysis and identification of impurities in pharmaceutical formulations. Its structural profile aids in the investigation of degradation products and the stability of related compounds, making it a valuable tool for quality control in drug development. -
Drug Impurity
Buspirone impurity 12 is a chemical impurity associated with the anxiolytic agent Buspirone. This compound is utilized in pharmaceutical research to assess the purity and quality of Buspirone formulations. Analytical studies involving Buspirone impurity 12 contribute to the understanding of drug metabolism, safety, and efficacy within clinical applications. -
Drug Impurity
Apixaban impurity 29 is a characterized impurity associated with the anticoagulant apixaban. It serves as a reference standard for analytical and quality control applications in pharmaceutical research. The identification and quantification of this impurity are essential for assessing the purity and safety of apixaban formulations. -
Drug Impurity
Ibrutinib Impurity 14 is a structural impurity associated with Ibrutinib, a selective inhibitor of Bruton's tyrosine kinase (BTK). This compound is utilized primarily in quality control and validation studies of Ibrutinib formulations. It serves as an important reference standard for assessing the purity and consistency of drug substances in pharmaceutical development. -
Drug Impurity
Erythromycin impurity 7 is a known impurity associated with the antibiotic Erythromycin. It serves as a critical reference standard in the analysis of drug formulations and quality control. This compound is essential for assessing the purity and stability of Erythromycin in pharmaceutical preparations, facilitating compliance with regulatory standards in drug development. -
Drug Impurity
Fluticasone impurity 4 is a known impurity associated with the corticosteroid fluticasone. This compound is crucial for analytical chemistry and quality control in pharmaceutical research, specifically during the evaluation of drug purity and stability. Its characterization aids in ensuring the compliance and efficacy of fluticasone formulations. -
Drug Impurity
Lopinavir impurity 11 is a chemical impurity associated with the antiviral drug Lopinavir. It serves as a reference standard for quality control and research applications related to the analysis of Lopinavir formulations. The characterization and quantification of this impurity are essential for ensuring the safety and efficacy of pharmaceutical products containing Lopinavir. This reagent facilitates the assessment of drug purity and compliance with pharmaceutical guidelines. -
Drug Impurity
Tamsulosin impurity 5 is a known impurity associated with Tamsulosin, a selective alpha-1 adrenergic receptor antagonist primarily used to treat benign prostatic hyperplasia. This specific impurity plays a crucial role in quality control and analytical studies aimed at evaluating the purity and stability of Tamsulosin formulations. It is essential for researchers focusing on the pharmacokinetics and safety profiles of the drug. -
Drug Intermediate
Dimecrotic acid is an organic acid that functions as a valuable drug intermediate in pharmaceutical synthesis. Its chemical properties facilitate the development of various therapeutic agents, supporting research in drug discovery and development. The compound is essential for creating complex organic molecules, thereby enhancing the efficiency of synthetic pathways in medicinal chemistry. -
Drug Impurity
Apixaban impurity 23 is a chemical impurity associated with the anticoagulant Apixaban. It serves as a critical reference standard for quality control and analytical studies in pharmaceutical research. The characterization of this impurity is essential for ensuring the safety and efficacy of Apixaban formulations. -
Drug Impurity
Erythromycin impurity 5 is a known impurity associated with the antibiotic erythromycin. It is primarily used in pharmaceutical research to assess the quality and safety of erythromycin formulations. This compound is essential for analytical chemistry studies, particularly in the development and refinement of drug purity standards. -
Drug Impurity
Mesalazine impurity 11 is a characterized impurity related to the anti-inflammatory agent Mesalazine. It serves as a critical reference standard in pharmaceutical research for quality control and method validation purposes. This compound is instrumental in evaluating the purity and safety profiles of Mesalazine formulations in compliance with regulatory standards. -
Drug Impurity
Testosterone impurity 7 is identified as a structural impurity of testosterone. This compound is utilized primarily in quality control and analytical studies to assess the purity of testosterone formulations. Its detection and characterization are critical for ensuring compliance with pharmacopoeial standards and validating the production process of testosterone-related products. -
Drug Impurity
Ethinylestradiol impurity 7, also known as 6,7-Dehydro Ethynyl Estradiol, is a drug impurity associated with Ethinylestradiol. This compound serves as a critical marker for assessing the purity and quality of Ethinylestradiol formulations. Its identification and quantification are essential in pharmaceutical research and regulatory compliance to ensure safe and effective use in various clinical applications.
